Drug Type Synthetic peptide |
Synonyms CLX 001 (ValiRx), CLX 001(ValiRx), CLX001 (ValiRx) + [1] |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Triple Negative Breast Cancer | Preclinical | United Kingdom | 15 Oct 2024 |